3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ChronoScale Holdings completed the sale of its Ekso Bionics subsidiary on September 30, 2026, and said it will focus on its AI infrastructure business. On October 1, 2026, it also announced an expanded agreement with an existing AI infrastructure customer and a new customer agreement, which together with existing contracts provide for $1 billion in annualized revenue run rate by calendar Q3 2027. The filing does not disclose the sale price or the company's profit results, and the revenue run-rate is a non-GAAP measure subject to deployment and financing risks.
Sale of Ekso Bionics, Inc., a wholly owned subsidiary, completed September 30, 2026; the filing does not state the sale price
Expanded AI infrastructure customer agreement and new customer agreement, announced October 1, 2026, with combined contracts targeting $1 billion annualized revenue run rate by calendar Q3 2027
Chief Operating Officer of Ekso, Jason C. Jones, terminated effective September 30, 2026, with severance of $243,750 plus up to nine months of COBRA premiums
Series B Convertible Preferred Stock designation withdrawn September 29, 2026; no preferred shares were outstanding
On October 1, 2026, UMH Properties declared a $0.225 quarterly common dividend and a $0.3984375 quarterly Series D preferred dividend, both payable December 15, 2026. It also reported preliminary third quarter 2026 figures showing gross home sales up 28% to $12.8 million from $10.0 million, and October rental and related income up 9.3% year over year, though these figures remain preliminary and unaudited until final results are released on November 2, 2026.
Common dividend of $0.225 per share, payable December 15, 2026, to holders of record on November 16, 2026; annual rate of $0.90 per share
Series D preferred dividend of $0.3984375 per share for September 1 to November 30, 2026, payable December 15, 2026
Q3 2026 gross home sales rose about 28% to $12.8 million from $10.0 million; the company said this broke its Q2 2026 quarterly sales record
Total rental and related income rose 9.3% for October 2026 versus October 2025; same store income rose 8.7%
Surrozen said the FDA cleared its Investigational New Drug application for SZN-8141, a treatment for diabetic macular edema, allowing clinical development to advance. The clearance satisfies a milestone for the second closing of its March 2025 private placement, which is expected to bring about $95.1 million in gross proceeds on or about October 20, 2026, before placement agent fees and other expenses.
FDA clearance of the SZN-8141 IND took effect after the statutory 30-day review period, announced October 2, 2026
First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026, with initial data expected in 2H 2027
Second closing of the March 2025 two-tranche private placement expected on or about October 20, 2026, with approximately $95.1 million in gross proceeds
Surrozen must file a Form S-3 resale registration statement within 30 calendar days after the closing
Hyperion DeFi, formerly Eyenovia, repaid its Avenue Capital loan in full on September 28, 2026, paying about $8.6 million with no early termination penalty, and says it has no long-term debt outstanding. The repayment was funded partly by sales of HYPE tokens, and the company has also begun repurchasing its common stock. The $14.5 million cash figure it reported is preliminary and unaudited.
September 28, 2026: repaid the Loan Agreement with Avenue Capital in full for about $8.6 million; liens were released and no early termination penalty was incurred.
Repayment was funded by HYPE token sales and cash on hand; 200,000 HYPE and HYPE liquid staking tokens were sold in the quarter ended September 30, 2026.
Repurchased 240,124 HYPD common shares at a weighted average gross price of $3.21 per share, as announced October 2, 2026.
As of September 30, 2026, cash, cash equivalents and USDC stablecoin totaled about $14.5 million (preliminary, unaudited); the company held 1.85 million Gross HYPE tokens.
On October 1, 2026, CareTrust completed the purchase of 24 completed UK care homes from LNT Care Developments for £576 million (about $764 million), excluding transaction costs. The company also expects to acquire 21 more homes under development for £504 million (about $669 million) on a rolling basis through December 31, 2027, and raised its full-year 2026 guidance, which shareholders may view as a sign of improved earnings expectations.
24 completed care homes acquired October 1, 2026 for £576 million (about $764 million), excluding transaction costs
21 in-development homes to be acquired for £504 million (about $669 million) as they are completed and approved, through December 31, 2027
Full-year 2026 guidance raised: net income attributable to CareTrust of $1.54 to $1.57 per share and Normalized FFO of $2.06 to $2.09 per share
Initial closing funded by proceeds from settling outstanding forward equity agreements and a draw on the revolving credit facility
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.